ALKERMES traded at $30.07 this Monday May 23rd, increasing $0.07 or 0.22 percent since the previous trading session. Looking back, over the last four weeks, ALKERMES gained 2.75 percent. Over the last 12 months, its price rose by 35.49 percent. Looking ahead, we forecast ALKERMES to be priced at 29.26 by the end of this quarter and at 26.10 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Otsuka Holdings 4,507.00 4.00 0.09% 0.83%
AbbVie 147.98 -3.03 -2.01% 27.67%
Acadia Pharmaceuticals 16.89 -0.22 -1.29% -23.02%
Acorda Therapeutics 0.51 -0.005 -0.95% -87.25%
Amgen 249.06 1.56 0.63% 0.53%
Biogen 199.47 -0.18 -0.09% -28.47%
Bluebird Bio 3.28 0.01 0.15% -89.62%
BioMarin Pharmaceutical 80.16 0.44 0.55% 3.37%
Bristol-Myers Squibb 76.70 0.51 0.67% 13.98%
Coherus Biosciences 8.33 0.02 0.24% -38.20%
Gilead Sciences 63.69 -0.15 -0.23% -5.55%
Heron Therapeutics 3.55 -0.06 -1.53% -73.74%
Horizon Pharma 87.31 -3.04 -3.36% -8.31%
Ionis Pharmaceuticals 39.33 -0.16 -0.41% 8.62%
Intra Cellular Therapies 58.52 0.64 1.10% 47.43%
Jazz Pharmaceuticals 148.45 -0.08 -0.05% -17.53%
J&J 179.47 2.49 1.41% 5.23%
Eli Lilly 302.72 3.87 1.29% 50.59%
H Lundbeck A/S 170.20 -0.50 -0.29% -14.08%
Merck & Co 93.84 0.29 0.31% 18.74%
Marinus Pharmaceuticals 5.57 0.25 4.70% -66.77%
Neurocrine Biosciences 87.07 0.89 1.03% -9.27%
Minerva Neurosciences 0.42 0.05 12.34% -86.56%
Nektar Therapeutics 3.70 -0.19 -4.77% -79.50%
Pfizer 52.90 0.43 0.82% 32.88%
Regeneron Pharmaceuticals 682.08 20.94 3.17% 36.29%
Revance Therapeutics 12.94 -0.83 -6.00% -53.87%
Teva Pharmaceutical Industries 8.61 0.14 1.65% -21.87%
Vertex Pharmaceuticals 268.35 9.76 3.77% 27.05%


ALKERMES
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.